Literature DB >> 10746656

Prevention of spontaneous autoimmune diabetes in NOD mice by transferring in vitro antigen-pulsed syngeneic dendritic cells.

G Papaccio1, F Nicoletti, F A Pisanti, K Bendtzen, M Galdieri.   

Abstract

To evaluate the effect of antigen-pulsed dendritic cell (DC) transfer on the development of diabetes, 5-week-old female NOD mice received a single iv injection of splenic syngeneic DC from euglycemic NOD mice pulsed in vitro with human y globulin (HGG). Eleven of 12 mice were protected from the development of diabetes up to the age of 25 weeks, and the insulitis score was significantly reduced. In contrast, NOD mice receiving unpulsed splenic DCs showed histological signs of insulitis and course of type 1 diabetes similar to untreated NOD mice. Treatment with HGG-pulsed DC was associated with profound modifications of cytokine secretory capacities within the islets. Thus, supernatants of islets from these mice contained increased levels of interleukin (IL)-4, IL-10, and, to a lesser extent, interferon-gamma and diminished levels of tumor necrosis factor-a compared with controls. Because exogenous IL-4 and IL-10 exert antidiabetogenic effect in NOD mice and early blockade of endogenous tumor necrosis factor-alpha prevents NOD mouse diabetes, these phenomena may be causally related to the antidiabetogenic effect of HGG-pulsed DC treatment.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10746656     DOI: 10.1210/endo.141.4.7437

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  18 in total

Review 1.  Dendritic cells, T cell tolerance and therapy of adverse immune reactions.

Authors:  P A Morel; M Feili-Hariri; P T Coates; A W Thomson
Journal:  Clin Exp Immunol       Date:  2003-07       Impact factor: 4.330

2.  Autoantigen-specific protection of non-obese diabetic mice from cyclophosphamide-accelerated diabetes by vaccination with dendritic cells.

Authors:  T Krueger; U Wohlrab; M Klucken; M Schott; J Seissler
Journal:  Diabetologia       Date:  2003-08-20       Impact factor: 10.122

Review 3.  Use of nonobese diabetic mice to understand human type 1 diabetes.

Authors:  Terri C Thayer; S Brian Wilson; Clayton E Mathews
Journal:  Endocrinol Metab Clin North Am       Date:  2010-07-08       Impact factor: 4.741

4.  Immunomodulatory dendritic cells require autologous serum to circumvent nonspecific immunosuppressive activity in vivo.

Authors:  Claus Haase; Mette Ejrnaes; Amy E Juedes; Tom Wolfe; Helle Markholst; Matthias G von Herrath
Journal:  Blood       Date:  2005-08-23       Impact factor: 22.113

Review 5.  Dendritic cell immunotherapy for autoimmune diabetes.

Authors:  Maryam Feili-Hariri; Rafael R Flores; A Cecilia Vasquez; Penelope A Morel
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

Review 6.  Targeted antigen delivery to DEC-205⁺ dendritic cells for tolerogenic vaccination.

Authors:  Cathleen Petzold; Sonja Schallenberg; Joel N H Stern; Karsten Kretschmer
Journal:  Rev Diabet Stud       Date:  2012-12-28

7.  Antigen-dependent immunotherapy of non-obese diabetic mice with immature dendritic cells.

Authors:  C Haase; L Yu; G Eisenbarth; H Markholst
Journal:  Clin Exp Immunol       Date:  2010-02-18       Impact factor: 4.330

8.  Vaccination with collagen-pulsed dendritic cells prevents the onset and reduces the disease severity in the mouse model of spontaneous polychondritis.

Authors:  M Sidhu; M M Griffiths; D S Bradley
Journal:  Clin Exp Immunol       Date:  2009-09       Impact factor: 4.330

9.  Passive transfer of flt-3L-derived dendritic cells delays diabetes development in NOD mice and associates with early production of interleukin (IL)-4 and IL-10 in the spleen of recipient mice.

Authors:  J Morin; B Faideau; M-C Gagnerault; F Lepault; C Boitard; S Boudaly
Journal:  Clin Exp Immunol       Date:  2003-12       Impact factor: 4.330

Review 10.  Immunomodulation of autoimmune diabetes by dendritic cells.

Authors:  Klaus Pechhold; Kerstin Koczwara
Journal:  Curr Diab Rep       Date:  2008-04       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.